Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Active Trials
    1(50%)

    Phase Distribution

    Phase 3
    1
    50%
    Phase 2
    1
    50%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    1

    Late Stage

    Phase Distribution2 total trials
    Phase 2Efficacy & side effects
    1(50.0%)
    Phase 3Large-scale testing
    1(50.0%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 0 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    1

    trials recruiting

    Total Trials

    2

    all time

    Status Distribution
    Active(1)
    Other(1)

    Detailed Status

    unknown1
    Recruiting1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    2
    Active
    1
    Success Rate
    N/A
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 21 (50.0%)
    Phase 31 (50.0%)

    Trials by Status

    unknown150%
    recruiting150%

    Recent Activity

    1 active trials
    Showing 2 of 2
    recruitingphase_2

    A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

    NCT05460000
    unknownphase_3

    Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation

    NCT01906814

    Clinical Trials (2)

    Showing 2 of 2 trials
    NCT05460000Phase 2

    A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

    Recruiting
    NCT01906814Phase 3

    Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation

    Unknown

    All 2 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    2